RxDoctor Payments Data

Jeffrey Tharp, MD

Internal Medicine · Hiram, GANPI 1336121557

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 152 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$401
  • Novo Nordisk$381
  • Amgen$316
  • Abbott$226
  • Pfizer$189
  • AbbVie$145
  • plus $925 from 23 others

What the payments were for

  • Food & beverage$2,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,582 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,688
Medicare patients
394
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$216,310
MounjaroTirzepatide106$112,043
JanuviaSitagliptin Phosphate90$109,505
JardianceEmpagliflozin52$60,300
XareltoRivaroxaban31$31,222
EliquisApixaban35$27,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$24,900
TradjentaLinagliptin19$22,747
FarxigaDapagliflozin Propanediol14$20,552
Tresiba Flextouch U-200Insulin Degludec18$15,700
MyrbetriqMirabegron29$14,984
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$12,132
Rosuvastatin Calcium691$9,393
LinzessLinaclotide11$8,854
Levothyroxine Sodium676$6,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$381$216,310213 claims
Lilly USA, LLCMounjaro$93$112,043106 claims
MerckJanuvia$12$109,50590 claims
Boehringer IngelheimJardiance, Tradjenta$81$83,04671 claims
Johnson & JohnsonXarelto$96$31,22231 claims
PfizerEliquis$189$27,42535 claims
GSKTrelegy Ellipta$59$24,90024 claims
Astellas Pharma US IncMyrbetriq$401$14,98429 claims
AbbVieLinzess, Synthroid$145$13,84270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Hiram

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →